$8B Loxo deal yields first drug with approval of Lilly’s targeted lung cancer therapy

FDA’s approval of Retevmo selpercatinib from Eli Lilly is the second approval for a genetically defined subset of non-small cell lung cancer patients this week.

The selective RET inhibitor is the first product of the $8 billion takeout of Loxo Oncology Inc. by Eli Lilly and Co. (NYSE:LLY) last year to reach the market, and reflects the pharma’s move from next-in-class drugs to first- and best-in-class agents...